ADARx wins FDA Fast Track for onvuzosiran in hereditary angioedema
ADARx Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration for onvuzosiran, its investigational small interfering RNA therapy aimed at preventing attacks of hereditary angioedema. The San Diego-based company said the designation reflects both the clinical data generated to date and the significant unmet need experienced by patients living with the condition.
Onvuzosiran works by suppressing prekallikrein production at the mRNA level, thereby reducing the availability of plasma kallikrein and limiting bradykinin generation. HAE, caused by an abnormality in the kallikrein-kinin cascade, produces recurrent and unpredictable episodes of painful, potentially life-threatening swelling. The candidate is currently being evaluated in the Phase 3 STOP-HAE trial.
Regulatory context
Fast Track status gives ADARx structured access to FDA reviewers throughout development, including more frequent meetings to discuss trial design and data requirements. It also enables rolling submission of a New Drug Application, allowing sections of the dossier to be reviewed as they are completed rather than waiting for a complete package. Eligibility for priority review remains conditional on meeting the relevant criteria at the time of filing.
The designation follows orphan drug status granted to onvuzosiran in October 2025, a combination that meaningfully de-risks the regulatory path. Orphan drug designation brings seven years of market exclusivity in the US on approval, alongside fee waivers and tax credits for clinical trial costs.
"As we continue to progress the Phase 3 trial, this marks an important milestone for the program," said Dr Zhen Li, President and Chief Executive Officer of ADARx.
Market landscape
The HAE prophylaxis market has become increasingly competitive over the past decade. Plasma kallikrein inhibition is an established therapeutic approach, with Takeda's subcutaneous lanadelumab and Beigene's licensed garadacimab among the approved and late-stage options targeting the same pathway. ADARx positions onvuzosiran as potentially superior on depth and durability of kallikrein suppression and on dosing frequency compared with current standards of care, though head-to-head data have not yet been disclosed and Phase 3 results will be required to substantiate those claims.
The broader siRNA therapeutics field has matured considerably since Alnylam's inclisiran and givosiran established the modality commercially. Several companies, including Silence Therapeutics and Arrowhead Pharmaceuticals, are advancing siRNA candidates across rare and common diseases, and the FDA has grown progressively more familiar with the regulatory requirements of the class. That institutional familiarity likely contributes to the relative efficiency with which ADARx has assembled its regulatory package, having now secured both orphan drug and Fast Track designations ahead of pivotal data readout.
ADARx additionally holds a collaboration and licence option agreement with AbbVie spanning siRNA programmes in neuroscience, immunology and oncology, providing a commercial validation of its platform beyond the HAE indication. Investors will focus on STOP-HAE enrolment progress and the timing of interim or topline data as the key near-term catalysts.